Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07049055 · ClinicalTrials.gov registry record · Phase 1
A Clinical Trial to Evaluate EDV Nanocell Therapy With Gemcitabine and Nab-paclitaxel in Pancreatic Cancer
A Phase 1 study of PDAC - Pancreatic Ductal Adenocarcinoma and Pancreatic Cancer Metastatic, sponsored by Engeneic Pty Limited.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 144
- Enrollment target
- 4
- Study locations
NCT07049055 is a Phase 1 study of PDAC - Pancreatic Ductal Adenocarcinoma and Pancreatic Cancer Metastatic that is actively recruiting participants, run by Engeneic Pty Limited. The registered enrollment target is 144 participants, below the 1,330-participant average among 10 other PDAC - Pancreatic Ductal Adenocarcinoma trials with a reported enrollment target (89% lower). The trial reports 4 study locations across 4 states.
The verdict
NCT07049055, a Phase 1 study of PDAC - Pancreatic Ductal Adenocarcinoma and Pancreatic Cancer Metastatic, is actively recruiting participants, sponsored by Engeneic Pty Limited.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 144 participants
- Enrollment target
- 4
- Study locations
Study Summary
The purpose of this study is to evaluate the safety and tolerability and overall survival (OS) of E-EDV-D682/GC in combination with gemcitabine and nab-paclitaxel versus gemcitabine and nab-paclitaxel alone in participants with metastatic pancreatic ductal adenocarcinoma (PDAC) who have progressed on therapy.
Conditions Studied
Interventions
- DRUG Gemcitabine
- DRUG E-EDV-D682
- DRUG EDV-GC
- DRUG Nab paclitaxel.
Study Locations (4)
California
- Chan Soon-Shiong Institute for Medicine - El Segundo
New Jersey
- Atlantic Health - Summit
New York
- Columbia University Irving Medical Center - New York
Ohio
- Taylor Cancer Center - Maumee
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 144 participants |
| Start Date | 2026-01-12 |
| Est. Completion | 2028-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07049055
The ClinicalTrials.gov registry entry for NCT07049055 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 144 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,330-participant average among 10 other PDAC - Pancreatic Ductal Adenocarcinoma trials with a reported enrollment target (89% lower). The listed sponsor is Engeneic Pty Limited, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with PDAC - Pancreatic Ductal Adenocarcinoma appearing as the primary indexed condition, and to 4 interventions - of which Gemcitabine is the first listed.
NCT07049055 reports 4 study locations spanning 4 distinct geographic areas - top geographies include California, New Jersey, New York.
Frequently Asked Questions
What is clinical trial NCT07049055 about?
NCT07049055 is a clinical study titled "A Clinical Trial to Evaluate EDV Nanocell Therapy With Gemcitabine and Nab-paclitaxel in Pancreatic Cancer". The purpose of this study is to evaluate the safety and tolerability and overall survival (OS) of E-EDV-D682/GC in combination with gemcitabine and nab-paclitaxel versus gemcitabine and nab-paclitaxel alone in participants with metastatic pancreatic ductal adenocarcinoma (PDAC) who have progressed o...
What is the current status of trial NCT07049055?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 144 participants. The study started on 2026-01-12. Estimated completion is 2028-09.
What conditions does trial NCT07049055 study?
This clinical trial studies the following conditions: PDAC - Pancreatic Ductal Adenocarcinoma, Pancreatic Cancer Metastatic.
What interventions are being tested in trial NCT07049055?
The interventions under investigation include: Gemcitabine (DRUG), E-EDV-D682 (DRUG), EDV-GC (DRUG), Nab paclitaxel. (DRUG).
Who is sponsoring clinical trial NCT07049055?
This trial is sponsored by Engeneic Pty Limited, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07049055 being conducted?
This trial has 4 study locations across California, New Jersey, New York, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for PDAC - Pancreatic Ductal Adenocarcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations
RECRUITING · Phase 1
-
Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patients
RECRUITING · Phase 1
-
BBO-11818 in Adult Subjects With KRAS Mutant Cancer
RECRUITING · Phase 1
-
AVA6103 in Subjects With Locally Advanced or Metastatic Selected Solid Tumors
RECRUITING · Phase 1
-
Study of TJ033721 (Givastomig) in Subjects With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
Prospective Screening for Pancreatic Ductal Adenocarcinoma in High-Risk Individuals
RECRUITING · Early Phase 1
Explore more on PlainTrial
PDAC - Pancreatic Ductal Adenocarcinoma
All registered trials for this condition
Pancreatic Cancer Metastatic
All registered trials for this condition
California
All trials with a study site in California
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.